Covalon Announces Voting Results from Fiscal 2020 Annual and Special Meeting of Shareholders

MISSISSAUGA, ON, July 2, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, announced today the results of the matters voted upon at its Fiscal 2020 Annual and Special Meeting of Shareholders ("AGM") held June 30th, 2021.

Shareholders voted in favour of all items of business and each item of business was approved by the requisite number of votes. The matters included the election of the Board of Directors, the appointment of auditors, and the approval of the Company's amended and restated stock option plan. The total number of shares represented, either in person or by proxy, totaled 11,030,811 or 42.72%. The voting results are detailed below.

1) The Election of the Board of Directors

Name of Nominee

Votes FOR

%

Votes WITHHELD

%

Amir Boloor

10,830,065

99.965

3,830

0.035

Joseph Cordiano

10,651,175

98.313

182,720

1.687

Myrna Francis

10,819,665

99.869

14,230

0.131

Martin Goldfarb

10,648,375

98.288

185,520

1.712

Brian Pedlar

10,678,175

98.563

155,720

1.437

Abe Schwartz

10,651,175

98.313

182,720

1.687

Ron Smith

10,830,065

99.965

3,830

0.035

2) The Appointment of the Auditor


Votes FOR

%

Votes WITHHELD

%

PricewaterhouseCoopers, LLP

11,023,056

99.930

7,755

0.070

3) The Approval of the Company's 2019 Amended and Restated Stock Option Plan


Votes FOR

%

Votes WITHHELD

%

Amended and Restated Stock Option Plan

10,590,575

97.754

243,320

2.246

Final voting results of all matters voted on at the meeting will be filed on SEDAR at www.sedar.com and further details of the voted matters can be found in the Company's management information circular dated May 26th, 2021. 

About Covalon

Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results, the impact and timing of COVID-19 on operating activities and market conditions and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

SOURCE Covalon Technologies Ltd.

For further information: To learn more about Covalon, please contact: Brian Pedlar, CEO, Covalon Technologies Ltd., Email: bpedlar@covalon.com, Phone: 905.568.8400 x 233, Toll-free: 1.877.711.6055, Website: www.covalon.com, Twitter: @covalon